Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02549651 · ClinicalTrials.gov registry record · Phase 1
MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT02549651 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 32 participants.
The verdict
NCT02549651, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of MEDI4736 (durvalumab) alone and in combination with either tremelimumab or AZD9150 in adult subjects with relapsed or refractory dIffuse large B-cell lymphoma.
Interventions
- DRUG MEDI4736
- DRUG tremelimumab
- DRUG AZD9150
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2016-07-13 |
| Est. Completion | 2019-02-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02549651
The ClinicalTrials.gov registry entry for NCT02549651 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which MEDI4736 is the first listed.
NCT02549651 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02549651 about?
NCT02549651 is a clinical study titled "MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)". The purpose of this study is to evaluate the safety, tolerability, and efficacy of MEDI4736 (durvalumab) alone and in combination with either tremelimumab or AZD9150 in adult subjects with relapsed or refractory dIffuse large B-cell lymphoma.
What is the current status of trial NCT02549651?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2016-07-13. Estimated completion is 2019-02-04.
What interventions are being tested in trial NCT02549651?
The interventions under investigation include: MEDI4736 (DRUG), tremelimumab (DRUG), AZD9150 (DRUG).
Who is sponsoring clinical trial NCT02549651?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.